Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.175
+0.145 (3.60%)
At close: Aug 13, 2025, 4:00 PM
4.180
+0.010 (0.24%)
Pre-market: Aug 14, 2025, 8:00 AM EDT
Cytek Biosciences Revenue
Cytek Biosciences had revenue of $45.60M in the quarter ending June 30, 2025, a decrease of -2.18%. This brings the company's revenue in the last twelve months to $196.04M, down -0.85% year-over-year. In the year 2024, Cytek Biosciences had annual revenue of $200.45M with 3.85% growth.
Revenue (ttm)
$196.04M
Revenue Growth
-0.85%
P/S Ratio
2.74
Revenue / Employee
$302,523
Employees
648
Market Cap
530.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 200.45M | 7.44M | 3.85% |
Dec 31, 2023 | 193.02M | 28.98M | 17.67% |
Dec 31, 2022 | 164.04M | 36.09M | 28.20% |
Dec 31, 2021 | 127.95M | 35.11M | 37.82% |
Dec 31, 2020 | 92.84M | 34.96M | 60.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2011 | Pro | Pro | Pro |
Dec 31, 2010 | Pro | Pro | Pro |
Dec 31, 2009 | Pro | Pro | Pro |
Dec 31, 2007 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CTKB News
- 1 day ago - Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 days ago - Cytek Biosciences, Inc. (CTKB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Cytek Biosciences Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer - GlobeNewsWire
- 2 months ago - Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Cytek Biosciences Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued? - Seeking Alpha